UPDATE: Allergan (AGN) Tops Q3 EPS by 9c

(Updated - November 1, 2017 7:09 AM EDT)

Allergan (NYSE: AGN) reported Q3 EPS of $4.15, $0.09 better than the analyst estimate of $4.06. Revenue for the quarter came in at $4.03 billion versus the consensus estimate of $4.03 billion.

It sees FY EPS of $16.15 - $16.45 vs consensus of $16.20 and GAAP revenue of $15.88-$16.03 billion vs consensus of $15.89 billion.

For earnings history and earnings-related data on Allergan (AGN) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• ACRES Commercial Realty says labor dispute is hindering hotel sale
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'